Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.
Finasteride and minoxidil are recommended for hair loss, with skepticism about additional treatments like electro stimulation and oxygen infusion, which are seen as ineffective and costly. Pulsed ultrasound may enhance drug delivery, but most other treatments are considered ineffective.
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
The conversation discusses whether rosemary oil can be applied directly to the scalp without dilution, with some users suggesting it is already diluted and safe to use. However, many emphasize that treatments like Minoxidil and Finasteride are more effective for hair loss, while rosemary oil is seen as less effective or a placebo.
The user experienced significant hair growth after using oral finasteride, topical minoxidil, and microneedling weekly for a year. They initially had low libido but resolved it by taking finasteride at night.
Using ketoconazole shampoo daily can dry out hair, and most users recommend using it 1-2 times a week with conditioner. Some users combine it with minoxidil and finasteride for better hair growth results.
The user experienced noticeable hair regrowth and darker beard after one month of using 1mg finasteride and 2.5mg minoxidil daily, with no side effects reported. They also started derma rolling two weeks ago and plan to continue the treatment for further results.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.
A dermatologist prescribed 0.5 mg dutasteride and 2.5 mg minoxidil for hair thinning, which is considered a solid regimen for regrowth. Users generally agree that dutasteride is more effective than finasteride and support the dermatologist's decision.
Sodium dodecyl sulfate, oleic acid, and palmitoleic acid may promote hair growth, but their safety and effectiveness for humans are uncertain. Users consider trying these treatments cautiously, exploring alternatives like ostrich oil and microneedling.
Topical dutasteride 0.05% is reported to outperform oral finasteride with minimal side effects, but concerns about study bias exist due to company funding. Some users report mixed results with topical dutasteride, noting issues with skin penetration and systemic absorption.
Microneedling with finasteride, minoxidil, DMSO, and black seed oil shows mixed hair regrowth results. There are concerns about DMSO's safety and effectiveness.
Minoxidil is highly toxic to pets, particularly cats and dogs, and there is a call for proper labeling to warn pet owners. Despite some skepticism about the effectiveness of petitions, many agree that awareness and caution are necessary to prevent accidental poisoning.
2-deoxy-D-ribose is being explored as a hair loss treatment but is not proven effective in humans and may be costly and inconvenient. Minoxidil remains the most effective treatment.
Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.
People are eagerly awaiting the release of PP405, a new hair loss treatment. Some are using minoxidil and finasteride in the meantime, but there are concerns about scams and unverified products.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
Minoxidil and finasteride are the main effective treatments for hair loss. RU58841 is discussed as a potential option but has concerns about safety and side effects.
Finasteride and Dutasteride are under review in the EU due to concerns about side effects like depression, but they are unlikely to be banned. Access to these medications varies, with easier availability in the UK compared to some EU countries.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
Higher doses of dutasteride for hair loss are debated, with some users suggesting they are unnecessary and potentially unsafe. The original poster uses a combination of dutasteride, minoxidil, and RU58841 for hair regrowth, despite concerns about high dosages.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.
The conversation is about a user experiencing positive hair regrowth results after using finasteride, minoxidil spray, dermapen, and low-level light therapy (LLLT) for four months. The user recommends using a specific device for LLLT and mentions using the Hims spray for finasteride and minoxidil.
A user shared their positive two-month progress using a hair loss treatment plan including finasteride, minoxidil, dermarolling, ketoconazole shampoo, and vitamins. They noted significant hair regrowth and thickness improvement, attributing success to the combination of treatments.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
A user is considering using redensyl with procapil instead of minoxidil to reduce hair fall. They are stressed about hair loss and seek community feedback on these treatments.